Synergistic Cytotoxic Effect from Combination of Wedelolactone and Cisplatin in HeLa Cell Line: A Novel Finding

References

• NIH National Cancer Institute. Surveillance, epidemiology and end results program; 2020 Available from:https://seer.cancer.gov/statfacts/html/cervix.html. Accessed 619, 2020.
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology™. Cervical Cancer. v1; 2012 Available from:http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed 821, 2020.
   Google Scholar
• KeysHM, BundyBN, StehmanFB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(1):1154–1161. doi:10.1056/NEJM199904153401503.10202166
   PubMed Web of Science ®Google Scholar
• RosePG, BundyBN, WatkinsEB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153. doi:10.1056/NEJM19990415340150210202165
   PubMed Web of Science ®Google Scholar
• WhitneyCW, SauseW, BundyBN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiotherapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynaecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–1348. doi:10.1200/JCO.1999.17.5.133910334517
   PubMed Web of Science ®Google Scholar
• MorrisM, EifelPF, LuJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–1143. doi:10.1056/NEJM19990415340150110202164
   PubMed Web of Science ®Google Scholar
• DueñasGA, ZarbáJJ, PatelF, et al. Phase III, open label randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678–1685. doi:10.1200/JCO.2009.25.966321444871
   PubMed Web of Science ®Google Scholar
• MonkBJ, SillMW, McMeekinDS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–4655. doi:10.1200/JCO.2009.21.890919720909
   PubMed Web of Science ®Google Scholar
• MooreDH, BlessingJA, McQuellonRP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113–3119. doi:10.1200/JCO.2004.04.17015284262
   PubMed Web of Science ®Google Scholar
• AranyI, SafirsteinRL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–464. doi:10.1016/S0270-9295(03)00089-5.13680535
   PubMed Web of Science ®Google Scholar
• LewandowskaU, GorlachS, OwczarekK, HrabecE, SzewczykK. Synergistic interactions between anticancer chemotherapeutics and phenolic compounds and anticancer synergy between polyphenols. Postepy Hig Med Dosw. 2014;68(1):528–540. doi:10.5604/17322693.1102278
   Web of Science ®Google Scholar
• XuT, PangQ, ZhouD, et al. Proteomic Investigation into betulinic acid-induced apoptosis of human cervical cancer HeLa cells. PLoS One. 2014;9(8):e105768. doi:10.1371/journal.pone.010576825148076
   PubMed Web of Science ®Google Scholar
• KilicU, SahinK, TuzcuM, et al. Enhancement of cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate. Front Nutr. 2014;1:28. doi:10.3389/fnut.2014.00028.25988128
   PubMedGoogle Scholar
• KarinM. Nuclear factor –kappa B in cancer development and progression. Nature. 2006;4419(7092):431–436. doi:10.1038/nature04870
   Web of Science ®Google Scholar
• ZhengX, LvJ, ShenQ, et al. Synergistic effect of pyrrolidine dithiocarbamate and cisplatin in human cervical carcinoma. Reprod Sci. 2014;21(10):1319–1325. doi:10.1177/193371911452527224594834
   PubMed Web of Science ®Google Scholar
• ZhuH, LuoH, ZhangW, ShenZ, HuX, ZhuX. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design Devel Ther. 2016;10(2):1885–1895. doi:10.2147/DDDT.S106412
   PubMed Web of Science ®Google Scholar
• SiddikZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279. doi:10.1038/sj.onc.120693314576837
   PubMed Web of Science ®Google Scholar
• DeanM, FojoT, BatesS. Tumor stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–284. doi:10.1038/nrc159015803154
   PubMed Web of Science ®Google Scholar
• WangX, MartindaleJL, HolbrookNJ. Requirement for ERK activation in cisplatin induced apoptosis. J Biol Chem. 2000;275(50):39435–39443. doi:10.1074/jbc.M00458320010993883
   PubMed Web of Science ®Google Scholar
• BasuA, TuH. Activation of ERK during DNA damage-induced apoptosis involves protein kinase C delta. Biochem Biophys Res Commun. 2005;334(4):1068–1073. doi:10.1016/j.bbrc.2005.06.19916039614
   PubMed Web of Science ®Google Scholar
• NegriA, NaponelliV, RizziF, BettuzziS. Molecular targets of epigallocatechin-gallate (EGCG): a special focus on signal transduction and cancer. Nutrients. 2018;10(12):1936. doi:10.3390/nu10121936
   PubMed Web of Science ®Google Scholar
• MillimounoFM, DongJ, YangL, LiJ, LiX. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res (Phila). 2014;7(11):1081–1107. doi:10.1158/1940-6207.CAPR-14-0136.25161295
   PubMed Web of Science ®Google Scholar
• ZhangX, HuJ, ChenY. Betulinic acid and the pharmacological effects of tumor suppression (Review). Mol Med Rep. 2016;14(5):4489–4495. doi:10.3892/mmr.2016.579227748864
   PubMed Web of Science ®Google Scholar
• DharaS. A rapid method for the synthesis of cis-[Pt (NH3)2Cl2]. Indian J Chem. 1970;8(1):193–194.
   Google Scholar
• MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method. 1983;65(1–2):55–63. doi:10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• ChouTC. Relations between inhibition constants and fractional inhibition on enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol. 1974;10(2):235–247.4212316
   PubMed Web of Science ®Google Scholar
• ChouTC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol. 1976;59(2):253–276. doi:10.1016/0022-5193(76)90169-7957690
   PubMed Web of Science ®Google Scholar
• KalraJ, WarburtonC, FangK, et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 2009;11(3):R25. doi:10.1186/bcr225219409087
   PubMed Web of Science ®Google Scholar
• BermanHM, WestbrookJ, FengZ, et al. The protein data bank. Nucleic Acids Res. 2002;28(1):235–242. doi:10.1093/nar/28.1.235.
   Web of Science ®Google Scholar
• MorrisGM, HueyR, LindstromW, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791. doi:10.1002/jcc.2125619399780
   PubMed Web of Science ®Google Scholar
• TrottO, OlsonAJ. AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.2133419499576
   PubMed Web of Science ®Google Scholar
• DallakyanS, OlsonAJ. Small-molecule library screening by docking with PyRx In: Hempel JE, Williams CH, Hong CC, Eds. Chemical Biology. New York, NY: Humana Press; 2015:243–250.
   Google Scholar
• LuoT, WangJ, YinY, et al. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 2010;12(1):R8. doi:10.1186/bcr247320078855
   PubMed Web of Science ®Google Scholar
• TallaridaRJ. Combination analysis. Adv Exp Med Biol. 2010;678(1):133–137.20738015
   PubMed Web of Science ®Google Scholar
• ZhuH, LuoH, ZhangW, ShenZ, HuX, ZhuX. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design Devel Ther. 2016;10(1):1885–1895. doi:10.2147/DDDT.S106412
   PubMed Web of Science ®Google Scholar
• ChenJ, XiongJ, LiuH, ChernenkoG, TangS. Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1 transfected C33A human cervical carcinoma cell line. Oncogene. 2002;21(46):7050–7059. doi:10.1038/sj.onc.120584512370827
   PubMed Web of Science ®Google Scholar
• SarveswaranS, GautamSC, GhoshJ. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via down regulation of PKCε without inhibiting Akt. Int J Oncol. 2012;41(6):2191–2199. doi:10.3892/ijo.2012.166423076676
   PubMed Web of Science ®Google Scholar
• VenderJR, LairdMD, DhandapaniKM. Inhibition of NFκB reduces cellular viability in GH3 pituitary adenoma cells. J Neurosurg. 2008;62(5):1122–1128. doi:10.1227/01.neu.0000325874.82999.75
   Web of Science ®Google Scholar
• ChaudharyH, DhunaV, SinghJ, KambojSS, SeshadriS. Evaluation of hydro-alcoholic extract of Eclipta alba for its anticancer potential: an in vitro study. J Ethnopharmacol. 2011;136(2):363–367. doi:10.1016/j.jep.2011.04.06621575697
   PubMed Web of Science ®Google Scholar
• SinghM, BhuiK, SinghR, ShuklaY. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci. 2013;93(1):7–16. doi:10.1016/j.lfs.2013.02.00123399702
   PubMed Web of Science ®Google Scholar
• HsiehCJ, KuoP, HouM, et al. Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. Int J Oncol. 2014;46(2):555–562. doi:10.3892/ijo.2014.276925421824
   PubMed Web of Science ®Google Scholar